RA Capital Management
Tracked across 23 events · 152 articles · First seen Apr 17, 2025 · Last active Aug 21, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: RA Capital Management, an activist investor with a 2.5% economic interest in Snap Inc., pushed for portfolio optimization, cost cuts, and the potential spin-off or shutdown of the Specs unit, influencing Snap Inc.'s recent actions.
Apr 15, 2026 · 15 articles
Business
Impact: RA Capital Management participated in the $180 million financing round for Bicara Therapeutics, demonstrating confidence in the company's drug development.
Jul 02, 2026 · 6 articles
Business
Werewolf Therapeutics and Ambros Therapeutics announced a definitive all-stock merger agreement to create a combined company focused on advancing neridronate, Ambros' late-stage treatment for Complex Regional Pain Syndrome Type 1 (CRPS-1). The combined company will…
Impact: RA Capital Management co-led the $150 million private placement, demonstrating strong investor confidence in the combined company's prospects. This investment is expected to yield significant returns if neridronate succeeds.
Aug 21, 2026 · 6 articles
Business
Impact: RA Capital Management, as the investment manager for both North American Financial 15 Split Corp. and North American Financial 15 Split Corp., advised their respective Boards of Directors that the share repurchases are in the best interests of the companies.
Jun 01, 2026 · 6 articles
Business
Impact: RA Capital Management acted as Corporate Finance Adviser, introducing investors for the placing and subscription for Novo Resources.
Apr 01, 2026 · 7 articles
Business
Impact: RA Capital Management, as the investment manager for Dividend 15 Split Corp. and Dividend 15 Split Corp. II, advised the Board of Directors that the share repurchases are in the best interests of the companies.
Jun 01, 2026 · 6 articles
Business
Fulcrum Therapeutics and Slate Medicines have signed a definitive all-stock merger agreement to create a combined company focused on next-generation migraine treatments. The combined entity will operate as Slate Medicines and trade on Nasdaq under…
Impact: RA Capital Management participated in the financing and will have board representation in the combined company.
Aug 17, 2026 · 6 articles
Business
Impact: RA Capital Management participated in the investment, contributing to the capital raised by Sana Biotechnology.
May 15, 2026 · 6 articles
Business
Impact: RA Capital Management LLC is a buy-side client of LinqAlpha, demonstrating the adoption and utility of LinqAlpha's platform among institutional investors.
Jul 02, 2026 · 6 articles
Business
Impact: RA Capital Management is a current Obsidian Therapeutics, Inc. investor participating in the private placement financing.
Apr 14, 2026 · 7 articles
ERGEN INTELLIGENCE
Track RA Capital Management live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard